SEARCH

SEARCH BY CITATION

References

  • 1
    Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infection: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, telavancin, and ceftaroline. Med Clin North Am 2011; 95: 723742.
  • 2
    Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested again methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005–2010). Diagn Microbiol Infect Dis 2011; 70: 412416.
  • 3
    Picazo JJ, Betriu C, Culebras E, et al. Staphylococcus aureus resistente a meticilina:sensibilidad a la daptomicina a lo largo de un periodo de 10 anos (2001–2010). Rev Esp Quimioter 2011; 24: 107111.
  • 4
    Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother 2011; 55: 41544160.
  • 5
    Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010; 10: 516521.
  • 6
    Fischer A, Yang SJ, Bayer AS, et al. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 2011; 66: 16961711.
  • 7
    Bertsche U, Weidenmaier C, Kuehner D, et al. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob Agents Chemother 2011; 55: 39223928.
  • 8
    Boyle-Vavra S, Jones M, Gourley BL, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 2011; 55: 20182025.
  • 9
    Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653665.
  • 10
    Goering RV, Ribot EM, Gerner-Smidt P. Pulsed-field gel electrophoresis laboratory and epidemiologic considerations for interpretation of data. In: Persing DH, Tenover FC, Tang YW, Nolte FS, Hayden IRT, Van Belkum A, eds. Molecular Microbiology, 2nd edn. Washington, DC: ASM Press, 2011; 167177.
  • 11
    Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin- susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 10081015.
  • 12
    Van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteremia in a daptomycin-naïve patient – a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30: 603610.
  • 13
    Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal B-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53: 158163.
  • 14
    Mehta S, Singh C, Plata KB, et al. B-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56: 61926200.
  • 15
    Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”). Antimicrob Agents Chemother 2010; 54: 31613169.